Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painsurgeryundergoinginfusionoperative
  Phrases that lowered it: protocolmaleablecriteria anyand female
• Sponsor's past termination rate: 25% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 57.3% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 9.1% (lowers risk) · Drug's FDA history
• Number of arms: 4 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 12 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 7 (lowers risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 2 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 13468 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion NCT03274453 · started 2012 · scored riskier than 97% of active trials completed
• A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain NCT05010148 · started 2021 · scored riskier than 86% of active trials completed
• Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery NCT04220489 · started 2019 · scored riskier than 57% of active trials terminated
• Perioperative Epidural Versus Intravenous Local Anesthetic Infusion in Open Upper Abdominal Surgery NCT03005171 · started 2017 · scored riskier than 8% of active trials completed
• Lidocaine Infusion for Major Abdominal Pediatric Surgery NCT01387568 · started 2010 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.